BACKGROUND & AIMS:
:MicroRNAs (miRNAs) are small non-coding RNA molecules, which act as post-transcriptional regulators of gene expression and have been implicated in initiation, progression and treatment outcome of diverse cancers. Single nucleotide polymorphisms (SNPs), as the most common type of genetic variation, also exist in miRNA genes and can lead to alteration in miRNA expression resulting in diverse functional consequences. Emerging studies have evaluated the association of miRNA SNPs with cancer risk, but the results remain inconclusive. To assess the relationship between miRNA SNPs and cancer risk, we performed a meta-analysis of 18 studies involving 20660 subjects for miR-146a rs2910164 polymorphism and 21 studies involving 26,018 subjects for miR-196a2 rs11614913 polymorphism. As for rs2910164, no significant association of cancer risk was found in the overall analysis. In subgroup analysis by cancer type, ethnicity, source of controls and sample size, significant association of cancer risk was mainly found in papillary thyroid carcinoma, primary liver cancer, cervical cancer, Caucasian population and small sample size studies. For rs11614913, significant results were found in all the tested genetic models and T allele or its carriers were associated with decreased cancer risk in overall analysis (T vs. C: OR = 0.888, 95% CI 0.84-0.938; TT+TC vs. CC: OR = 0.897, 95% CI 0.828-0.971). In stratified analysis by cancer type and ethnicity, significant association of cancer risk was observed in breast cancer, lung cancer, colorectal cancer and Asian population, but not in Caucasian population. During further stratified analysis by source of controls and sample size, results similar to those of overall analysis were found in all of the subgroups. Taken together, our results indicated that miR-196a2 rs11614913 T variant probably contribute to decreased susceptibility to cancer. However, limited evidence was found for association of miR-146a rs2910164 with cancer risk, and further well-designed studies with large sample size will be necessary to validate the effect of miR-146a rs2910164 on cancer susceptibility.
背景与目标:
:MicroRNA(miRNA)是小的非编码RNA分子,可作为基因表达的转录后调节剂,并与多种癌症的发生,进展和治疗结果有关。单核苷酸多态性(SNP)是最常见的遗传变异类型,也存在于miRNA基因中,并可导致miRNA表达发生变化,从而导致多种功能后果。新兴研究已经评估了miRNA SNP与癌症风险之间的关系,但结果尚无定论。为了评估miRNA SNP与癌症风险之间的关系,我们对18项涉及20660名miR-146a rs2910164多态性受试者的研究和21项涉及26018名miR-196a2 rs11614913多态性受试者的研究进行了荟萃分析。至于rs2910164,在总体分析中未发现明显的癌症风险关联。在按癌症类型,种族,控制源和样本量进行的亚组分析中,癌症风险的显着相关性主要发现于甲状腺乳头状癌,原发性肝癌,宫颈癌,高加索人群和小样本量研究中。对于rs11614913,在所有测试的遗传模型中均发现了显着结果,并且在整体分析中T等位基因或其携带者与降低癌症风险相关(T vs. C:OR = 0.888,95%CI 0.84-0.938; TT TC vs. CC :OR = 0.897,95%CI 0.828-0.971)。在按癌症类型和种族进行的分层分析中,在乳腺癌,肺癌,大肠癌和亚洲人群中观察到了癌症风险的显着关联,而在白种人人群中则没有。在按控制源和样本量进行的进一步分层分析中,在所有亚组中均发现了与总体分析相似的结果。综上所述,我们的结果表明miR-196a2 rs11614913 T变体可能有助于降低对癌症的敏感性。然而,发现miR-146a rs2910164与癌症风险相关的证据有限,因此,有必要进一步设计良好的大样本研究来验证miR-146a rs2910164对癌症易感性的影响。